Geptanolimab (CBT-501) is a Anti-PD-1 Monoclonal Antibody for Solid Tumor Research
In this article, we will introduce a potent humanized IgG4k monoclonal antibody against programmed death-1 (PD-1) Geptanolimab. As a result, Geptanolimab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. As a result, Geptanolimab (CBT-501) has highly specific binding to PD-1 of humans (KD=505 pM) and cynomolgus...
Olutasidenib, a Brain-Penetrant Mutant IDH1 Selective Inhibitor For AML Research
On December 1, 2022, FDA approved Rezlidhea (Olutasidenib) to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible (IDH1) mutation. Olutasidenib (FT2102) is a highly potent, orally active, brain-penetrant, and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). As a result, The IC50 values are...
SOR-C13 is a High-Affinity TRPV6 Antagonist for Advanced Solid Tumors Research
The Vanilloid group (TRPV) contains six members, from TRPV1 to TRPV6. TRPV5 and TRPV6 exhibit lower sequence identity to V1-V4, and different properties. Additionally, TRPV5 or TRPV6 is selective for calcium ions. The major function of TRPV5/6 is larger-scale calcium homeostasis. Besides, Mice with TRPV6 knock-outs exhibit defective intestinal...
Rucaparib is a PARP Inhibitor
PARP is a family of proteins involved in many cellular processes, such as DNA repair, genomic stability, and programmed cell death. At least 18 members of the PARP family are encoded by different genes and have homology in conserved catalytic domains. Specifically, PARPs play an important role in various...